Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Special protocol assessment process for the dipeptidyl peptidase inhibitor would have delayed start of Phase III non-small cell lung cancer trials, exec says.

You may also be interested in...



Point Therapeutics’ Oncologic Talabostat On Clinical Hold

Poor interim trial results, cash crunch may force Boston company to reduce operations.

Point Therapeutics’ Oncologic Talabostat On Clinical Hold

Poor interim trial results, cash crunch may force Boston company to reduce operations.

FDA Workshop To Discuss Brain Tumor Trial Endpoints

The Jan. 20 public meeting is next in a series of meetings on oncology endpoints.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel